.jpg)
What We Do
We manage patient-specific supply chains, end-to-end, from the provider’s point of view
Our closed-loop supply chain manifests itself around our patented Precision Medicine Vessel (PMV), an IoT patient specimen container that serves as a tracking device throughout the treatment lifecycle, digitizing the physical events that occur, and recording them to a distributed ledger.
​
Broadly, ImmunoChain is a management platform for advanced therapies like autologous cell transfers in which cells are extracted from a source patient, augmented and expanded in a lab, then reinfused or implanted back into the source patient.
​​
Our unique combination of cloud infrastructure and hardware makes ImmunoChain the only platform that can truly manage Chain of Custody without trust, just verification.
NO
PORTALS
NO
SPREADSHEETS
NO
EMAILS
NO
PHONE CALLS
Drug Wholesalers
Insurance
Labs
3PL
Manufacturers
How does ImmunoChain address the complexity?
The conundrum of managing personalized medicine treatments like CAR T is that the patient’s specimen is both the input and the output of the supply chain. The specimen changes form over the course of a circuitous exchange of custody between various stakeholders with diverging incentives. Every step requires an exchange of information and/or physical action to manage chain of custody, chain of identity, and chain of form (i.e., the sequence of form changes). ImmunoChain facilitates the treatment lifecycle and captures all data within it, ensuring control and full surveillance of the process.
ImmunoChain manages each patient’s treatment as an individual supply chain.
​
The platform continuously monitors each step of the treatment lifecycle and adjusts actions based on feedback along the value chain
The ImmunoChain platform provides unrivaled transparency and workflow management for personalized treatments.
A New Frontier
Precision medicine is personalized medicine, and it is revolutionizing health care. In particular, cancer care. Doctors can now tailor treatments to a specific patient by extracting their cells and modifying them to target and destroy cancer cells. Demand for these therapies is growing at double-digits.
New treatments are coming to market and cold chain logistics is playing an ever larger role in how those treatments are developed and executed. It is a new frontier in supply chain management.
We believe our technology can scale the advanced operational infrastructure needed for precision medicine.
Our platform plays the role of a command center, providing end-to-end visibility as each patient's cells are transformed into their treatment. This level of transparency will spur new levels of operational excellence and set the standard for how precision medicine is managed.
Visibility spans the entire supply chain, from extraction through specimen preparation, shipment, PO placement and order processing, manufacturing, receiving, and distribution.
Leadership
Noah Fichter
Founder & CEO
Noah Fichter is the Founder & CEO of ImmunoChain. As a staunch advocate for healthcare providers and a thought leader in expanding patient access, he created ImmunoChain in 2021 to meet the clear need for a provider-focused Supply Chain standard in advanced therapies.
He also currently serves as the Director of Supply Chain Informatics & Business Intelligence at Memorial Sloan Kettering Cancer Center (MSKCC). Since joining MSKCC in 2017, Noah has spearheaded initiatives that identified ~$450M in cash flow improvements. He was also an early adopter of cloud computing to standardize and automate supply chain capabilities in hospital operations.
Prior to his tenure at MSKCC, Noah spent a decade at Thermo Fisher Scientific, a global leader in biotechnology product development within the scientific research and healthcare industries. Notably, during his time there, he lived and worked in Mumbai, India, where he led efforts to streamline manufacturing and distribution capabilities for the Asian market. Additionally, he managed demand planning for life sciences and pharmaceutical supplies across the U.S. and Europe, working on projects ranging from chemical manufacturing to molecular spectroscopy.
Noah holds a Bachelor of Science degree in Transportation & Logistics from The Ohio State University and an MBA from the Tepper School of Business at Carnegie Mellon University.